These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11125296)

  • 1. The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma.
    Barillé S; Bataille R; Amiot M
    Eur Cytokine Netw; 2000 Dec; 11(4):546-51. PubMed ID: 11125296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
    Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble IL-6R alpha upregulated IL-6, MMP-1 and MMP-2 secretion in bone marrow stromal cells.
    Barillé S; Collette M; Thabard W; Bleunven C; Bataille R; Amiot M
    Cytokine; 2000 Sep; 12(9):1426-9. PubMed ID: 10976008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepcidin and multiple myeloma related anemia.
    Cucuianu A; Patiu M; Rusu A
    Med Hypotheses; 2006; 66(2):352-4. PubMed ID: 16226391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1.
    Jourdan M; De Vos J; Mechti N; Klein B
    Cell Death Differ; 2000 Dec; 7(12):1244-52. PubMed ID: 11175262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential regulation of interleukin-6 receptors by interleukin-6 and interferons in multiple myeloma cell lines.
    Lasfar A; Wietzerbin J; Billard C
    Eur J Immunol; 1994 Jan; 24(1):124-30. PubMed ID: 8020547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
    Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
    Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signalling and survival pathways in multiple myeloma.
    Bommert K; Bargou RC; Stühmer T
    Eur J Cancer; 2006 Jul; 42(11):1574-80. PubMed ID: 16797970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma.
    Gadó K; Domján G; Hegyesi H; Falus A
    Cell Biol Int; 2000; 24(4):195-209. PubMed ID: 10816321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-6 in multiple myeloma and related plasma cell dyscrasias.
    Treon SP; Anderson KC
    Curr Opin Hematol; 1998 Jan; 5(1):42-8. PubMed ID: 9515202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis.
    Nowell MA; Richards PJ; Fielding CA; Ognjanovic S; Topley N; Williams AS; Bryant-Greenwood G; Jones SA
    Arthritis Rheum; 2006 Jul; 54(7):2084-95. PubMed ID: 16802343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM
    Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin 6 (IL-6) and its receptor: their role in plasma cell neoplasias.
    Hirano T
    Int J Cell Cloning; 1991 May; 9(3):166-84. PubMed ID: 2061619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloma cells release soluble interleukin-6Ralpha in relation to disease progression by two distinct mechanisms: alternative splicing and proteolytic cleavage.
    Thabard W; Barillé S; Collette M; Harousseau JL; Rapp MJ; Bataille R; Amiot M
    Clin Cancer Res; 1999 Oct; 5(10):2693-7. PubMed ID: 10537331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
    Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6 trans-signaling in inflammatory bowel disease.
    Mitsuyama K; Sata M; Rose-John S
    Cytokine Growth Factor Rev; 2006 Dec; 17(6):451-61. PubMed ID: 17045835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Directly linked soluble IL-6 receptor-IL-6 fusion protein induces astrocyte differentiation from neuroepithelial cells via activation of STAT3.
    Takizawa T; Yanagisawa M; Ochiai W; Yasukawa K; Ishiguro T; Nakashima K; Taga T
    Cytokine; 2001 Mar; 13(5):272-9. PubMed ID: 11243705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
    Giuliani N; Colla S; Morandi F; Rizzoli V
    Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
    Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-6 from intrahepatic cells of bone marrow origin is required for normal murine liver regeneration.
    Aldeguer X; Debonera F; Shaked A; Krasinkas AM; Gelman AE; Que X; Zamir GA; Hiroyasu S; Kovalovich KK; Taub R; Olthoff KM
    Hepatology; 2002 Jan; 35(1):40-8. PubMed ID: 11786958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.